New Treatments for Female Sexual Dysfunction: Are they Safe and Effective for Older Post-Menopausal Women?
Purpose of Review
Several new modalities for treatment of female sexual function problems have been approved by the US Food and Drug Administration (FDA). This review summarizes current evidence about recently approved medications to inform treatment of sexual function problems in women older than 65 years.
Published studies leading to FDA approval of treatment modalities were efficacy trials not widely applicable to the general population. The clinical effectiveness of these modalities remains unknown. Although some studies have included post-menopausal women, few have included women older than 65 years.
Health care providers need current information about safety and effectiveness of these new treatments for all women, including the fast-growing population of older post-menopausal women. Exclusion of older women from studies of treatments for female sexual function problems presents a barrier to treatment.
KeywordsSexual dysfunction Post-menopausal Women
Stacy Tessler Lindau reports a grant from the Ellie Fund at Jewish Women’s Foundation of Metropolitan Chicago to the University of Chicago; reports being a member of the board of the Scientific Network on Female Sexual Health and Cancer; reports being a founder, co-owner, and investor in NowPow, LLC; reports investments in Glenbervie Health; reports stocks and mutual funds, including some with healthcare relevance, that are managed by third parties; and reports being contracted to be a peer reviewer for UpToDate, which will pay small fees to the University of Chicago for this activity.
Compliance with Ethical Standards
Conflict of Interest
Janelle Sobecki-Rausch declares no potential conflicts of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: •• Of major importance
- 1.Ortman JM, Velkoff VA, Hogan H. An aging nation: the older population in the United States. Suitland: United States Census Bureau, Economics and Statistics Administration, US Department of Commerce; 2014.Google Scholar
- 4.US Food and Drug Administration Drugs@FDA: FDA Approved Drug Products. www.accessdata.fda.gov/scripts/cder/daf. Accessed October 18, 2018.
- 8.Soe LH, Wurz GT, Kao CJ, DeGregorio MW. Ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy: potential benefits in bone and breast. Int J Health. 2013;5(1):605–11.Google Scholar
- 10.Bachmann GA, Komi JO, Group OS. Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study. Menopause. 2010;17(3):480–6.Google Scholar
- 13.Simon J. Efficacy and safety of daily ospemifene 60 mg for up to 1 year when used in the treatment of vulvar and vaginal atrophy in postmenopausal women. Menopause. 2012;19(12):1397–8.Google Scholar
- 14.Simon J, Bachmann G, Goldstein S, Lin V, Portman D, Phelps M. Evaluation of the safety of daily ospemifene 60 mg for up to 1 year when used in the treatment of vulvar and vaginal atrophy in postmenopausal women. Climacteric. 2011;14(suppl 1):87.Google Scholar
- 15.Simon JA, Lin VH, Radovich C, Bachmann GA, Group OS. One-year long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus. Menopause. 2013;20(4):418–27.Google Scholar
- 24.Portman DJ, Johnson D, Yuan J, Barbour K, Kissling R. Flibanserin in postmenopausal women with hypoactive sexual desire disorder: results of the PLUMERIA study. Menopause. 2016;23(12):1393.Google Scholar
- 28.Labrie F, Archer DF, Koltun W, Vachon A, Young D, Frenette L, et al. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause. 2016;23(3):243–56.CrossRefGoogle Scholar
- 30.Society NAM. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society. Menopause (New York, NY). 2007;14(3 Pt 1):355.Google Scholar
- 31.Constantine GD, Simon JA, Pickar JH, Archer DF, Kushner H, Bernick B, et al. The REJOICE trial: a phase 3 randomized, controlled trial evaluating the safety and efficacy of a novel vaginal estradiol soft-gel capsule for symptomatic vulvar and vaginal atrophy. Menopause. 2017;24(4):409–16.CrossRefGoogle Scholar
- 32.•• Constantine GD, Bouchard C, Pickar JH, Archer DF, Graham S, Bernick B, et al. Consistency of effect with a low-dose, estradiol vaginal capsule (TX-004HR): evaluating improvement in vaginal physiology and moderate-to-severe dyspareunia in subgroups of postmenopausal women. J Women’s Health. 2017;26(6):616–23 Age-related efficacy analysis performed in a population of women 62 years or older. CrossRefGoogle Scholar
- 33.Sobecki-Rausch JN, Brown O, Gaupp CL, editors. Sexual dysfunction in lesbian women: a systematic review of the literature. Seminars in reproductive medicine. Stuttgart: Thieme Medical Publishers; 2017.Google Scholar
- 35.Centers for Medicare and Medicaid Services CMS Fast Facts. https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/CMS-Fast-Facts/index.html. Accessed October 18, 2018.
- 36.Centers for Medicare and Medicaid Services Prescription Drug Benefit Manual Chapter 6. https://www.cms.gov/Medicare/Prescription-Drug-Coverage/PrescriptionDrugCovContra/Downloads/Part-D-Benefits-Manual-Chapter-6.pdf.
- 37.Centers for Medicare and Medicaid Services Formulary Guidance CY19 Formulary Reference FIle https://www.cms.gov/Medicare/Prescription-Drug-Coverage/PrescriptionDrugCovContra/RxContracting_FormularyGuidance.html. Accessed October 28, 2018.